Long-term safety of risperidone

J Clin Psychiatry. 2001;62 Suppl 21:26-8.

Abstract

In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day). During 12-month, open-label extensions to these studies, the incidence of de novo tardive dyskinesia was very low. No clinically significant adverse events, changes in vital signs, or laboratory signs were observed. In summary, the safety and tolerability of risperidone in treating elderly dementia sufferers has been favorable in several clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / pharmacokinetics
  • Antipsychotic Agents / therapeutic use
  • Basal Ganglia Diseases / chemically induced
  • Basal Ganglia Diseases / epidemiology
  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / therapeutic use
  • Clinical Trials as Topic / statistics & numerical data
  • Dementia / drug therapy*
  • Dementia / psychology
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / epidemiology
  • Dyskinesia, Drug-Induced / etiology
  • Humans
  • Incidence
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / metabolism
  • Receptors, Histamine / drug effects
  • Receptors, Histamine / metabolism
  • Receptors, Muscarinic / drug effects
  • Receptors, Muscarinic / metabolism
  • Risperidone / adverse effects*
  • Risperidone / pharmacokinetics
  • Risperidone / therapeutic use
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Antipsychotic Agents
  • Cholinesterase Inhibitors
  • Receptors, Dopamine
  • Receptors, Histamine
  • Receptors, Muscarinic
  • Risperidone